Nachrichten zur Bristol-Myers Squibb Co. Aktie

Bristol Myers Squibb Co. stock falls Thursday, underperforms market

Shares of Bristol Myers Squibb Co. slipped 0.75% to $51.47 Thursday, on what proved to be an all-around great trading…

Bristol-Myers Squibb: A Nice Deal For This Bargain Pharma Stock

…

ALLR: Stenoparib Clinical Update

By John Vandermosten, CFA NASDAQ:ALLR Early Results - Phase II Stenoparib Allarity Therapeutics, Inc. (NASDAQ:ALLR) provided an update to investors on its…

: Bristol Myers adds $3 billion to share buyback program to boost total to about $5 billion

Bristol Myers Squibb Co. BMY announced an additional $3 billion share buyback program on Thursday, boosting the full authorization to…

: Bristol Myers Squibb raises dividend by 5.3%

Bristol Myers Squibb Co. BMY said late Wednesday that its board has declared a quarterly dividend of 60 cents a…

Multiple Myeloma Market revenue to surpass USD 71 Billion by 2035, says Research Nester

Major multiple myeloma market players include Amgen Inc., Johnson & Johnson, Takeda Pharmaceuticals Company Limited, Novartis AG, Sanofi, Teva Pharmaceuticals…

Global Melanoma Therapeutics Market Size To Worth USD 12.35 Billion By 2032 | CAGR of 9.4%

The Global Melanoma Therapeutics Market Size was valued at USD 5.03 Billion in 2022 and the Worldwide Melanoma Therapeutics Market…

Bristol Myers Squibb new CEO buys company shares

…

Bristol Myers Squibb CEO Chris Boerner Buys Up Stock

…

Fortunes Can Be Made With Bristol-Myers Squibb

Taking a closer look at one of the largest companies in the pharmaceutical industry…

[Latest] Global Organ Transplantation Market Size/Share Worth USD 21.5 Billion by 2032 at a 9.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Non-Oncology Biologics and Biosimilars Market is Booming and Expected to Grow at a CAGR of 21.8% to 2031

Companies covered in this report are AbbVie Inc., Sanofi, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La…

Avidity Biosciences leaps on Bristol-Myers research tie-up

Avidity Biosciences soared 35% in pre-market trading after announcing a global licensing and research collaboration with Bristol-Myers Squibb Co...…

Bristol-Myers Squibb Is A Great Buy, But These 5+% Yielding Bargains Are Better

…

: Avidity’s stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone payments

Avidity Biosciences Inc. RNA said Tuesday it’s expanding its cardiovascular collaboration with Bristol Myers Squibb Co. BMY in a deal…

Global Non-Hodgkin Lymphoma Therapeutics Market Size To Worth USD 16.64 Billion by 2032 | CAGR of 7.8%

The Global Non-Hodgkin Lymphoma Therapeutics Market Size was valued at USD 7.85 Billion in 2022. The Worldwide Non-Hodgkin Lymphoma Therapeutics…

Bristol-Myers Squibb: The Patent Expiry Challenge

…

Bristol Myers Squibb: A Bitter Pill But Still A Buy

…

Oncology Drug Discovery & Development Market Expected to Grow at a CAGR of 18.2% from 2023 to 2031 | Reveals InsightAce Study

Companies covered in this study are Novartis, AstraZeneca, Merck & Co., Inc, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Gilead…

Bristol-Myers Squibb: A Tough But Cheap Spot

…

Bristol Myers (BMY), TSVT Cell Therapy Abecma Faces Setback

Bristol Myers Squibb (BMY) and 2seventy bio, Inc.s efforts to seek approval for the label expansion of Abecma for earlier…

Dow Jones, S&P 500, Nasdaq: US-Anleger kaufen weiter ein

Bei den Einzelwerten geben die Aktien von Bristol Myers Squibb zum Handelsstart um rund vier Prozent nach. Dabei spielt auch…

Bristol Myers Squibb slumps as FDA convenes advisory panel for drug application By Investing.com

Bristol Myers Squibb slumps as FDA convenes advisory panel for drug application…

Bristol-Meyers Squibb shares fall as FDA delays blood cancer therapy decision

Bristol-Myers Squibb Co (NYSE:BMY) shares fell almost 5% after the company announced that a Food and Drug Administration (FDA) decision…

Bristol-Myers Squibb: Bayer-Nachrichten sind ein schlechtes Omen - Aktienanalyse

London (www.aktiencheck.de) - Bristol-Myers Squibb-Aktienanalyse von Barclays: Die Analysten von Barclays stufen die Aktie von Bristol-Myers Squibb Company (ISIN: US1101221083, WKN:…

Stocks making the biggest premarket moves: Boeing, Bristol-Myers Squibb, Chegg, Krispy Kreme and more

These are the stocks posting the largest moves in the premarket.…

: Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment

Shares of Bristol Myers Squibb, 2seventy bio fell early Monday as FDA said it would miss a regulatory action date…

Biggest stock movers today: Bristol Myers Squibb, NuScale Power, Chegg and more

…

Bayer Stock Plunges, Bristol Myers Squibb Falls After Negative Drug-Trial Result

The week is off to an ugly start for some pharmaceutical investors. Bayer said it is halting a trial for asundexian,…

Bristol Myers Squibb: Bright Future Ahead

…

Bristol Myers Squibb shares dip as market shows mixed results By Investing.com

Bristol Myers Squibb shares dip as market shows mixed results…

Bristol-Myers Squibb Company (BMY) Management Presents at Jefferies London Healthcare Conference (Transcript)

…

Bristol-Myers Squibb slashed, Energizer hit with 3 downgrades: 4 big analyst cuts By Investing.com

Bristol-Myers Squibb slashed, Energizer hit with 3 downgrades: 4 big analyst cuts…

Hypertrophic Cardiomyopathy Treatment Market to Exhibit Impressive Growth by 2023, Predicts DelveInsight | Key Companies - Cytokinetics, Bristol-Myers Squibb, Imbria Pharmaceuticals, Inc., Tenaya Therapeutics, Novartis

The hypertrophic cardiomyopathy market dynamics are anticipated to change during the forecast period (2023–2032) due to the expected launch of…

dpa-AFX ProFeed